Cardiovascular Events and Parathyroid Hormone—Suggestion of a Further Link : Journal of the American Society of Nephrology

Journal Logo

Nephrology beyond JASN

Cardiovascular Events and Parathyroid Hormone—Suggestion of a Further Link

Rashid, G.; Bernheim, J.; Green, J.; Benchetrit, S.

Journal of the American Society of Nephrology 18(4):p 1023-1026, April 2007. | DOI: 10.1681/ASN.2007020240
  • Free


Eberhard Ritz:
Feature Editor

For a long time it has been suspected that parathyroid hormone (PTH) plays a causal role in the genesis of the high cardiovascular risk in uremia. The recent discovery, using vitamin D receptor (VDR) knockout mice, that 1,25(OH)2 D3 inhibits renin secretion from the juxtaglomerular apparatus (1) and that uninhibited renin secretion in VDR knockout mice causes cardiac hypertrophy and other sequelae, as well as the observation of reduced mortality in dialysis patients on active vitamin D (2), have somewhat stolen the limelight from PTH as a potential cardiovascular culprit. The above communication comes as a timely and welcome reminder that PTH can certainly not entirely be discounted.

In their study, Rashid and colleagues studied confluent cultures (passage 2-4) of human umbilical vein endothelial cells (HUVEC), a work horse for studies on endothelial cell function, which they exposed to clinically relevant concentrations (10−12 to 10−10 mol/L) of 1,34-PTH for 24 to 72 h. The main read-out was the receptor for advanced glycation end products (RAGE) as well as IL-6. The main finding was that 1,34-PTH at these concentrations increased the mRNA as well as the protein expression (Western blot) of RAGE. Furthermore, it increased the mRNA but not the secretion (by ELISA) of IL-6.

The authors then proceeded to determine the signaling pathways responsible for the effect of 1,34-PTH. To this end they first pretreated the culture for 30 min with the protein kinase C (PKC) inhibitor Calphostin and the protein kinase A (PKA) antagonist Rp-cAMP. Both inhibitors caused a significant decrease of RAGE mRNA and RAGE protein expression to the level in untreated cells, indicating that both the PKC and PKA pathways are involved. This is in contrast to what is seen in vascular smooth muscle cells where only the pathway via adenylate cylase and PKA is activated (3), but similar to what is seen in most other PTH target cells, including renal epithelia.

Because nitric oxide (NO) is an endothelial cell signaling substance of particular importance, the authors also pretreated the cultures with L-NAME, the inhibitor of NO synthase. Such pretreatment also inhibited RAGE mRNA and protein expression, as well as IL-6 mRNA. This finding argues in favor of a role for endothelial NO synthase (eNOS) and NO in the RAGE and IL-6 expression and is consistent with previous findings of activation of eNOS by PTH (4).

As a caveat it must be realized that the HUVEC model has limitations as to how far it can be generalized to apply to endothelial cells of other vascular territories.

Nevertheless, what are the implications of this finding? The relationship between cardiovascular events or mortality and intact PTH concentrations has been postulated for a long time (5), but the evidence remains shaky because the relationship is complex: both high and low PTH concentrations predict increased mortality depending on the accompanying changes of calcium and phosphate (6).

It is illustrative to have a look at primary hyperparathyroidism, where many of the confounding factors of secondary hyperparathyroidism are not operative, although minor disturbances of renal function may be a confounder in primary hyperparathyroidism as well. In a large national Swedish registry, mortality was increased in patients with primary hyperparathyroidism (7), and increased cardiovascular risk or mortality in patients with secondary hyperparathyroidism was found in many other studies as well (810). Two recent retrospective analyses found that long-term mortality was reduced after parathyroidectomy by approximately 15% (11,12). Long-term data on cardiovascular events and survival in patients on calcimimetics and their relatively selective lowering of PTH are eagerly awaited; cardiovascular benefit would give a new dimension to this compound (13). Past experimental studies have already shown lower blood pressure (14), less morphologic abnormalities of the heart, and lower lipid levels (15).

Endothelial cells express PTH/PTHrp (PTH-related protein) receptors (16), as do may other organs unrelated to mineral homeostasis (17), such as the vasculature (18,19). In uremia the PTH/PTHrp receptor is downregulated in many organs (e.g., the heart [20], the kidney [21] or osteoblasts [22]). In the context of vascular disease and atherosclerosis, implied by the above authors as a potential corollary of their findings, it is of particular interest that Marti[Combining Acute Accent]n-Ventura et al. (23), when analyzing inflammatory atherosclerotic plaques of the carotid artery by immunohistochemistry, documented high expression of PTHrp, PTH/PTHrP receptor, and the proinflammatoty chemokine monocyte chemoattractant protein 1 (MCP-1) in the unstable shoulder of the plaques. Such expression was colocalized with inflammatory cells. In vitro studies with vascular smooth muscle cells (not endothelial cells as in the above study) showed that PTHrp increased MCP-1 mRNA, an effect that was specifically inhibited by the inhibitory peptide PTHrp (734), by protein kinase inhibitors, or by parthenolide, a specific the inhibitor of nuclear factor κB. Evidence of increased expression of PTHrp in lesioned vessels has also been provided by other authors (24,25). The N-terminal fragment of PTHrp is a potent vasodilator and either stimulates or inhibits growth of vascular cells depending on the experimental conditions (19,26). It is unresolved whether circulating 1,84-PTH (and in the above in vitro studies) acts via the type 1 PTH/PTHrp receptor just as an analog of the autocrine/paracrine local PTHrp, so to speak as a cuckoo's egg.

Of particular interest in the above study is the observation that PTH upregulated the expression of RAGE. RAGE is a multiligand receptor of the Ig superfamily of cell surface molecules and acts as a pattern recognition receptor; in other words, the receptor does not interact with a single specific ligand, but with a broad spectrum of molecules, e.g., advanced glycation products (AGE), but also with high-molecular group box 1- protein, S100/calgranulins, and amyloid-β peptides (27,28). RAGE also serves as an endothelial adhesion receptor for leukocyte integrins and promotes leukocyte recruitment and extravasation. Activation of RAGE increases the activity of proinflammatory nuclear factor κB, the long-acting inflammatory master switch. It has been argued that this mechanism converts transient cellular stimuli into sustained cellular dysfunction (27,28). This link between RAGE and inflammation has been summarized in several reviews (29). In our study, expression of RAGE was increased in endothelial cells of nondiabetic uremic patients (30).

This novel potential link between PTH and vascular injury is definitely of interest, but when assessing the impact of PTH on cardiovascular risk, other PTH-induced abnormalities must also be considered, e.g., the effects on cardiomyocytes with increased heart rate, calcium uptake, mitochondrial malfunction, and necrosis of cardiomyocytes (31,32), as well as activation of interstitial cardiac fibroblasts (33) and thickening of postcoronary arteries (34), not to forget indirect effects, e.g., on tissue and vascular calcification.

Although the study, like all good studies, raises more questions than it answers, it is certain to stimulate rethinking of entrenched opinions on this subject.

Address correspondence to: Prof. Eberhard Ritz, Department Internal Medicine, Division of Nephrology, Bergheimer Strasse 56a, D-69115 Heidelberg, Germany. Phone: +49-0-6221-601705 or +49-0-6221-189976; Fax: +49-0-6221-603302; E-mail: [email protected]


1. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110 : 229 –238, 2002
2. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16 : 1115 –1125, 2005
3. Schluter KD, Piper HM: Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 37 : 34 –41, 1998
4. Rashid G, Benchetrit S, Green J, Bernheim J: The stimulatory effect of parathyroid hormone on the eNOS system is through cAMP and protein kinase (PKC) pathways [Abstract]. ERA-EDTA Congress (Glasgow), 2006
5. Massry SG, Goldstein DA: The search for uremic toxin(s) “X” “X” = PTH. Clin Nephrol 11 : 181 –189, 1979
6. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A: Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 15 : 770 –779, 2004
7. Hedback G, Oden A: Increased risk of death from primary hyperparathyroidism—An update. Eur J Clin Invest 28 : 271 –276, 1998
8. Stefenelli T, Abela C, Frank H, Koller-Strametz J, Globits S, Bergler-Klein J, Niederle B: Cardiac abnormalities in patients with primary hyperparathyroidism: Implications for follow-up. J Clin Endocrinol Metab 82 : 106 –112, 1997
9. Piovesan A, Molineri N, Casasso F, Emmolo I, Ugliengo G, Cesario F, Borretta G: Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 50 : 321 –328, 1999
    10. Palmer M, Adami HO, Bergstrom R, Akerstrom G, Ljunghall S: Mortality after surgery for primary hyperparathyroidism: A follow-up of 441 patients operated on from 1956 to 1979. Surgery 102 : 1 –7, 1987
    11. Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, Sherrard DJ, Stehman-Breen C: Survival following parathyroidectomy among United States dialysis patients. Kidney Int 66 : 2010 –2016, 2004
    12. Foley RN, Li S, Liu J, Gilbertson DT, Chen SC, Collins AJ: The fall and rise of parathyroidectomy in US hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 16 : 210 –218, 2005
    13. Schmitt CP, Odenwald T, Ritz E: Calcium, calcium regulatory hormones, and calcimimetics: Impact on cardiovascular mortality. J Am Soc Nephrol 17 : S78 –S80, 2006
    14. Odenwald T, Nakagawa K, Hadtstein C, Roesch F, Gohlke P, Ritz E, Schaefer F, Schmitt CP: Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats. J Am Soc Nephrol 17 : 655 –662, 2006
    15. Ogata H, Ritz E, Odoni G, Amann K, Orth SR: Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14 : 959 –967, 2003
    16. Jiang B, Morimoto S, Yang J, Niinoabu T, Fukuo K, Ogihara T: Expression of parathyroid hormone/parathyroid hormone-related protein receptor in vascular endothelial cells. J Cardiovasc Pharmacol 31[Suppl 1] : S142 –S144, 1998
    17. Bro S, Olgaard K: Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 30 : 606 –620, 1997
    18. Philbrick WM, Wysolmerski JJ, Galbraith S, Holt E, Orloff JJ, Yang KH, Vasavada RC, Weir EC, Broadus AE, Stewart AF: Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol Rev 76 : 127 –173, 1996
    19. Clemens TL, Cormier S, Eichinger A, Endlich K, Fiaschi-Taesch N, Fischer E, Friedman PA, Karaplis AC, Massfelder T, Rossert J, Schluter KD, Silve C, Stewart AF, Takane K, Helwig JJ: Parathyroid hormone-related protein and its receptors: Nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets. Br J Pharmacol 134 : 1113 –1136, 2001
    20. Smogorzewski M, Tian J, Massry SG: Down-regulation of PTH-PTHrP receptor of heart in CRF: Role of [Ca2+]i. Kidney Int 47 : 1182 –1186, 1995
    21. Urena P, Kubrusly M, Mannstadt M, Hruby M, Trinh MM, Silve C, Lacour B, Abou-Samra AB, Segre GV, Drueke T: The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int 45 : 605 –611, 1994
    22. Picton ML, Moore PR, Mawer EB, Houghton D, Freemont AJ, Hutchison AJ, Gokal R, Hoyland JA: Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int 58 : 1440 –1449, 2000
    23. Martin-Ventura JL, Ortego M, Esbrit P, Hernandez-Presa MA, Ortega L, Egido J: Possible role of parathyroid hormone-related protein as a proinflammatory cytokine in atherosclerosis. Stroke 34 : 1783 –1789, 2003
    24. Nakayama T, Ohtsuru A, Enomoto H, Namba H, Ozeki S, Shibata Y, Yokota T, Nobuyoshi M, Ito M, Sekine I, Yamashita S: Coronary atherosclerotic smooth muscle cells overexpress human parathyroid hormone-related peptides. Biochem Biophys Res Commun 200 : 1028 –1035, 1994
    25. Ozeki S, Ohtsuru A, Seto S, Takeshita S, Yano H, Nakayama T, Ito M, Yokota T, Nobuyoshi M, Segre GV, Yamashita S, Yano K: Evidence that implicates the parathyroid hormone-related peptide in vascular stenosis. Increased gene expression in the intima of injured carotid arteries and human restenotic coronary lesions. Arterioscler Thromb Vasc Biol 16 : 565 –575, 1996
    26. Massfelder T, Dann P, Wu TL, Vasavada R, Helwig JJ, Stewart AF: Opposing mitogenic and anti-mitogenic actions of parathyroid hormone-related protein in vascular smooth muscle cells: A critical role for nuclear targeting. Proc Natl Acad Sci U S A 94 : 13630 –13635, 1997
    27. Bierhaus A, Humpert PM, Stern DM, Arnold B, Nawroth PP: Advanced glycation end product receptor-mediated cellular dysfunction. Ann N Y Acad Sci 1043 : 676 –680, 2005
    28. Bierhaus A, Stern DM, Nawroth PP: RAGE in inflammation: A new therapeutic target? Curr Opin Investig Drugs 7 : 985 –991, 2006
    29. Yan SF, Ramasamy R, Naka Y, Schmidt AM: Glycation, inflammation, and RAGE: A scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93 : 1159 –1169, 2003
    30. Greten J, Kreis I, Wiesel K, Stier E, Schmidt AM, Stern DM, Ritz E, Waldherr R, Nawroth PP: Receptors for advance glycation end-products (AGE)—Expression by endothelial cells in non-diabetic uraemic patients. Nephrol Dial Transplant 11 : 786 –790, 1996
    31. Bogin E, Massry SG, Harary I: Effect of parathyroid hormone on rat heart cells. J Clin Invest 67 : 1215 –1227, 1981
    32. Bogin E, Levi J, Harary I, Massry SG: Effects of parathyroid hormone on oxidative phosphorylation of heart mitochondria. Miner Electrolyte Metab 7 : 151 –156, 1982
    33. Amann K, Ritz E, Wiest G, Klaus G, Mall G: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4 : 1814 –1819, 1994
    34. Amann K, Tornig J, Flechtenmacher C, Nabokov A, Mall G, Ritz E: Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia: Evidence for a permissive action of PTH. Nephrol Dial Transplant 10 : 2043 –2048, 1995
    Copyright © 2007 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.